The U.S. Food and Drug Administration’s advisers on Tuesday unanimously recommended that the agency approve Moderna Inc.’s MRNA.O COVID-19 vaccine for children and adolescents ages 6 to 17.
Approximately 77 million people in the United States have received a course of at least two doses of the Moderna vaccine, which has long been available to people 18 years of age or older.
The committee of external experts on Wednesday shot Moderna shots for children under 6, and Pfizer PFE.N and BioNTech’s 22UAy.DE COVID vaccines for children under 5 – and in both cases under 6 months. Set to consider children.
Moderna shots are unlikely to be in immediate demand for children between the ages of 6 and 17. The Pfizer / BioNTech vaccine was adopted in October for children aged 5 to 11 years, and was approved for adolescents months earlier.
Yet in the United States, about 30 percent of people between the ages of 5 and 11 and 60 percent of people between the ages of 12 and 17 have been fully vaccinated.
Dr. Arthur Rangold, a member of the committee and professor at UC Berkeley, told the meeting, “I would like to give parents as many choices as possible, and let them make decisions for their children.”
The FDA – which normally follows the advice of its advisers but is not bound to do so – is likely to soon approve the Moderna vaccine for 6-17 year olds. The CDC also needs to recommend the use of vaccines. A committee of its advisers will meet on Friday and Saturday.
There have long been concerns that the modern vaccine, which is given in higher doses than the Pfizer / BioNTech shot, could cause the types of heartburn called myocarditis and pericarditis at higher rates, primarily less. In older men.
Some European countries have limited use of the Moderna vaccine to younger groups when surveillance suggested it was linked to an increased risk of heartburn, and the FDA used shots to assess the risk of myocarditis. Review delayed.
U.S. regulators presented data at Tuesday’s meeting stating that the Moderna vaccine may increase the risk of heart disease in adolescents, but said the results were not consistent across different safety databases and statistically. Were not important, that is, they may be due to chance.